(주)프로젠

{
  "address": "서울특별시 강서구",
  "ceo_name": "김종균",
  "certificate": [
    {
      "cert_number": "1999163612-0726",
      "changes": "",
      "disclosure_date": "1999-06-03",
      "first_cert_date": "1999-06-03",
      "no": "1",
      "type": "기타",
      "valid_period": "1999-06-03 ~ 2000-12-31"
    },
    {
      "cert_number": "20001622122583",
      "changes": "",
      "disclosure_date": "2000-12-21",
      "first_cert_date": "1999-06-03",
      "no": "2",
      "type": "기타",
      "valid_period": "2000-12-21 ~ 2002-12-20"
    },
    {
      "cert_number": "20180103366",
      "changes": "",
      "disclosure_date": "2018-03-29",
      "first_cert_date": "1999-06-03",
      "no": "3",
      "type": "연구개발유형",
      "valid_period": "2018-03-29 ~ 2020-03-28"
    },
    {
      "cert_number": "20200108319",
      "changes": "",
      "disclosure_date": "2020-06-22",
      "first_cert_date": "1999-06-03",
      "no": "4",
      "type": "연구개발유형",
      "valid_period": "2020-03-29 ~ 2022-03-28"
    },
    {
      "cert_number": "20220428010044",
      "changes": "",
      "disclosure_date": "2022-04-28",
      "first_cert_date": "1999-06-03",
      "no": "5",
      "type": "벤처투자유형",
      "valid_period": "2022-03-29 ~ 2025-03-28"
    },
    {
      "cert_number": "20250408010012",
      "changes": "",
      "disclosure_date": "2025-04-08",
      "first_cert_date": "1999-06-03",
      "no": "6",
      "type": "벤처투자유형",
      "valid_period": "2025-03-29 ~ 2028-03-28"
    }
  ],
  "company_name": "주식회사 프로젠",
  "corp_no": "134511-*******",
  "financials": {
    "2022": {
      "capital_stock": 3356000000,
      "cost_of_sales": 0,
      "current_assets": 3953231000,
      "current_liabilities": 14620974000,
      "gross_profit": 450000000,
      "net_income": -17333974000,
      "net_income_bs": -17333974000,
      "non_current_assets": 49250399000,
      "non_current_liabilities": 21017062000,
      "non_operating_expenses": 9975296000,
      "non_operating_income": 290666000,
      "operating_profit": -7649344000,
      "revenue": 450000000,
      "sga_expenses": 8099344000,
      "total_assets": 53203630000,
      "total_equity": 17565594000,
      "total_liabilities": 35638036000
    },
    "2023": {
      "capital_stock": 9535287000,
      "cost_of_sales": 26100000,
      "current_assets": 9490891000,
      "current_liabilities": 22413365000,
      "gross_profit": 1078940000,
      "net_income": -16616209000,
      "net_income_bs": -16616209000,
      "non_current_assets": 77546706000,
      "non_current_liabilities": 27043499000,
      "non_operating_expenses": 6778538000,
      "non_operating_income": 481432000,
      "operating_profit": -10319103000,
      "revenue": 1105040000,
      "sga_expenses": 11398043000,
      "total_assets": 87037598000,
      "total_equity": 37580733000,
      "total_liabilities": 49456864000
    }
  },
  "industry": "의학 및 약학 연구개발업",
  "investment": [
    {
      "amount": "2,498,500,000",
      "changes": "2,498,500,000",
      "date": "2022-02-04"
    },
    {
      "amount": "10,020,000,000",
      "changes": "10,020,000,000",
      "date": "2018-09-19"
    }
  ],
  "main_products": "신약연구개발",
  "phone": "02-6098-****",
  "years": [
    2023,
    2022
  ]
}